100例鲍曼不动杆菌的耐药性与整合子表达及耐药基因分析

目的 了解鲍曼不动杆菌的耐药性和整合子表达及耐药基因携带情况.方法 收集100株鲍曼不动杆菌,以VITEK-64系统鉴定细菌,并进行14种抗生素药敏试验,通过PCR法检测Ⅰ、Ⅱ、Ⅲ类整合酶基因(intI1、2、3)及Ⅰ类整合子可变区基因盒,并对基因盒测序.结果 除阿米卡星和头孢哌酮/舒巴坦,鲍曼不动杆菌对其他12种抗菌药物耐药率均大于60.0％,多重耐药率为88.0％.鲍曼不动杆菌整合酶基因阳性率为64.0％,均为intI1,整合子阳性菌株对多数药物的耐药率显著高于整合子阴性者(P＜0.05).intI1阳性菌株中,84.4％ (54/64)扩增出整合子可变区,检出3种耐药基因盒组合形式:aac(6’)-Ib-cr-arr-3-dfrA27 14株、aacA4-catB8-aadA1 24株、aacC1-orfA-orfB-aadA1 16株.结论 临床分离的鲍曼不动杆菌多重耐药与Ⅰ类整合子表达有关.Ⅰ类整合子主要携带早期使用的氨基糖苷类抗菌药、甲氧苄啶和氯霉素耐药基因.     

鲍曼不动杆菌整合子介导耐药机制的初步研究

【摘 要】 目的 研究整合子参与鲍曼不动杆菌耐药的分子机制。结果 收集2008年1月至2011年12月瑞安市中医院临床分离的200株鲍曼不动杆菌,采用K-B法进行体外药敏试验,采用聚合酶链式反应进行整合子整合酶基因的检测;整合子可变区扩增、克隆、测序,分析整合子基因结构。结果 59.0%的医院感染鲍曼不动杆菌Ⅰ类整合子阳性,未检测出Ⅱ、Ⅲ类整合子;编码对氨基糖苷类、磺胺类抗菌药物和氯霉素耐药的基因;整合子阳性组多药耐药菌均明显高于阴性组。结论 Ⅰ类整合子在医院感染鲍曼不动杆菌中广泛分布,可通过质粒在不同菌属间水平传播,在耐药基因传播中起重要作用,应引起临床足够的重视。     

鲍曼不动杆菌整合子分型与耐药性的初步研究

目的了解临床分离的43株鲍曼不动杆菌中Ⅰ类、Ⅱ类、Ⅲ类整合子的流行病学现状及其耐药性。方法用多重PCR方法扩增30株鲍曼不动杆菌Ⅰ类、Ⅱ类、Ⅲ类整合酶基因,用K—B法检测鲍曼不动杆菌的耐药情况。结果Ⅰ类整合子检出率为79．1％（34／43）,未检出Ⅱ、Ⅲ类整合子。结论Ⅰ类整合子阳性的菌株的耐药率较高,显著高于Ⅰ类整合子阴性的菌株,多重PCR是筛查革兰阴性杆菌整合子的有效方法。     

多重耐药鲍曼不动杆菌耐药性及β-内酰胺酶耐药基因的研究

研究多重耐药鲍曼不动杆菌的耐药性及β-内酰胺酶耐药基因的携带情况。采用VIKET Compact 2 全自动细菌鉴定系统进行细菌鉴定,采用纸片扩散法（K-B法）测定鲍曼不动杆菌对抗菌药物的耐药性,应用聚合酶链反应（PCR）法检测β-内酰胺酶耐药基因。32株多重耐药鲍曼不动杆菌对13种常用抗菌药物的耐药率均>80%,对亚胺培南和美罗培南耐药率分别高达78.1%和71.9%,头孢哌酮/舒巴坦耐药率31.3%,多粘菌素B抗菌活性最好,耐药率0%。检出超广谱β-内酰胺酶（ESBLs）和头孢菌素酶（AmpC）耐药基因,未检出金属β-内酰胺酶（MBLs）耐药基因。32株多重耐药鲍曼不动杆菌TEM基因均阳性,17株检出PER基因,29株检出ADC基因。有16株菌同时携带TEM、PER、ADC基因。结果表明,同时携带TEM、PER、ADC基因是安徽医科大学解放军174临床学院鲍曼不动杆菌产生多重耐药性的原因之一。     

鲍曼不动杆菌临床分离株的耐药性及同源性分析

目的 通过对重庆医科大学附属第二医院近4年临床分离的103株鲍曼不动杆菌的耐药性和同源性分析,了解该院鲍曼不动杆菌的耐药性特点及院内感染流行状况.方法 2008年至2011年间该院临床科室分离的103株鲍曼不动杆菌,进行药敏试验并对耐药性分析;提取细菌基因组DNA,以随机扩增DNA多态性(RAPD)方法进行基因分型.结果 药敏试验结果显示分离出的103株菌呈现出高耐药率及多重耐药率的特点,其中对左氧氟沙星和亚胺培南的耐药性最低,分别为69.9％和57.3％.103株多重耐药鲍曼不动杆菌用RAPD分型共分为16种基因型:A～P,其中A型84株,为主要流行型别;B型3株;C型、G型各2株;其余12型各1株.结论 该院鲍曼不动杆菌具有多重耐药及高耐药率,可能存在以A型鲍曼不动杆菌克隆株传播方式的院内流行,临床上应加强对A型鲍曼不动杆菌的监控,采取有效的措施以预防院内感染的爆发流行.     

泰安渿河中产ESBLs大肠杆菌耐药性及耐药基因的传递规律

【目的】调查城市河流泰安市渿河(贯穿城区)中产超广谱β-内酰胺酶(extended-spectrum β-lactamases,ESBLs)大肠杆菌的分布及其多重耐药性与耐药基因携带情况,探究其耐药基因传递规律。【方法】采用Kirby-Bauer法测定耐药表型,用PCR和基因序列测定法进行耐药基因、整合子检测和多位点序列分型,并进行细菌接合试验。【结果】从272份水样中分离88株产ESBLs大肠杆菌,分离率32.4%,多重耐药率为59.1%。耐药基因检测出blaTEM、qnrS、AacC2、aac(6’)-Ib-cr、oqxA、OXA、AacC4,携带率分别为94.3%、33.0%、29.5%、12.5%、11.4%、6.8%、5.6%,59.0%菌株携带多种耐药基因。MLST分型检测出47种ST型,ST38为主要分型占13.6%,发现ST131两株。I类整合子检出率26.1%,其中,dfrA17-aadA5阳性率为13.6%。接合率为83.0%(73/88),72.6%的接合子发生耐药谱变窄,供体菌所携带的七种耐药基因均发生了水平传递。【结论】城市河流中细菌多重耐药现象严重且耐药性可水平传递,存在城市公共卫生安全隐患。     

鲍曼不动杆菌对碳青霉烯类抗生素的耐药性分析

目的了解鲍曼不动杆菌的耐药情况,并检测耐碳青霉烯类鲍曼不动杆菌的耐药基因,为指导临床合理用药、控制院内感染提供依据。方法利用K-B法检测45株鲍曼不动杆菌临床分离株的耐药情况,通过改良Hodge试验、Carba NP试验和EDTA协同试验对多重耐药鲍曼不动杆菌的碳青霉烯酶进行表型检测,并采用PCR技术检测鲍曼不动杆菌携带OXA-23和NDM-1型耐药基因的情况。结果 45株鲍曼不动杆菌临床分离株中共筛出42株多重耐药菌株;利用改良Hodge试验和Carba NP试验检出36株碳青霉烯酶阳性菌株;采用PCR扩增出OXA-23,未扩增出NDM-1。结论鲍曼不动杆菌耐药情况严重,且耐药基因OXA-23携带率高,治疗时应根据药敏试验结果合理用药。     

临床分离鲍曼不动杆菌的外排泵基因检测及同源性分析

目的探讨临床分离鲍曼不动杆菌主动外排基因的分布和菌株克隆相关性,为指导临床合理用药和制定恰当的感染控制措施提供理论依据。方法对临床分离的80株鲍曼不动杆菌采用琼脂稀释法检测对抗菌药物的敏感性,聚合酶链反应(PCR)检测adeB、adeG、adeJ外排泵基因的携带情况,脉冲场凝胶电泳法分析多重耐药鲍曼不动杆菌的同源性。结果 80株临床分离鲍曼不动杆菌中,57株为多重耐药株(MDRAB),且对多粘菌素B、头孢哌酮/舒巴坦和美罗培南较为敏感,对其他临床常用抗生素普遍耐药。adeB、adeG、adeJ外排泵基因分布广泛,在敏感菌株中存在率也很高;PFGE分型结果显示57株MDRAB菌株共分为四大群(A、B、C、D),并以流行克隆A为主。结论临床分离鲍曼不动杆菌耐药形式严峻,其临床分离株普遍存在外排泵编码基因adeB、adeG、adeJ,携带外排泵阳性MDRAB菌株的克隆播散是温州地区鲍曼不动杆菌发生耐药的机制之一。     

主动外排机制在鲍曼不动杆菌耐药性中的作用

目的探讨细菌主动外排机制在临床分离的鲍曼不动杆菌耐药性中的作用。方法琼脂稀释法检测临床分离的鲍曼不动杆菌对常用抗生素的耐药性,测定经外排泵抑制剂碳酰氰基-对-氯苯腙（CCCP）处理前后鲍曼不动杆菌对抗生素最小抑菌浓度（MIC）的变化,以聚合酶链反应（PCR）、逆转录-聚合酶链反应（RT-PCR）检测多重耐药主动外排基因以出及其表达水平。结果临床分离的鲍曼不动杆菌对常用抗生素耐药率高且具有多重耐药性,并存在药物的主动外排。所有临床分离的菌株均能检测到adeB基因,但多重耐药株表达水平明显高于敏感株（P〈0．01）。结论临床分离的鲍曼不动杆菌的耐药性尤其是多重耐药性与外排泵介导的耐药机制密切相关。     

近三年鲍曼不动杆菌耐药性变迁及外排泵基因研究

目的研究鲍曼不动杆菌的耐药性变迁及外排泵基因携带情况,为控制医院感染提供依据。方法运用纸片扩散法检测我院2015-2017年临床分离的鲍曼不动杆菌对18种抗菌药物的耐药性,并对耐药性变化趋势进行分析。PCR技术检测多重耐药菌adeB、adeJ、adeE、abeM四种外排泵基因的携带情况。结果三年时间共分离出鲍曼不动杆菌385株,检出数量逐年升高,以呼吸科和重症医学科为主,分别占32.7%和28.3%。药敏结果显示鲍曼不动杆菌对多黏菌素B (0.0%)、替加环素(0.0%～1.6%)耐药率最低,其次为头孢哌酮舒巴坦(22.9%～32.0%)。三年来鲍曼不动杆菌对左氧氟沙星、亚胺培南、美罗培南耐药率有显著升高,超过20%,对庆大霉素、阿米卡星耐药率下降超过10%。172株多重耐药菌(44.7%)中,PCR扩增结果显示adeB和adeJ阳性率分别为76.7%和51.2%,并有5株(2.91%)检出adeE基因。结论近三年鲍曼不动杆菌耐药性呈上升趋势,外排泵是导致其耐药的机制之一。     

Distribution of class 1 integrons among enteropathogenic Escherichia coli

The aim of this study was to investigate the incidence of and resistance gene content of class 1 integrons among enteropathogenic Escherichia coli (EPEC) and non-EPEC and to investigate intraspecies genetic diversity of EPEC strains isolated from children with diarrhea in Iran. Twenty-eight EPEC and 16 non-EPEC strains isolated from children with diarrhea were tested for the presence of a class 1 integron associated integrase gene (int1). Sequence analysis was performed to identify the resistance gene content of integrons. Genetic diversity and cluster analysis of EPEC isolates were also investigated using enterobacterial repetitive intergenic concensus-polymerase chain reaction (ERIC-PCR) fingerprinting. Twenty-three (82%) EPEC isolates and 11 (68.7%) non-EPEC isolates harbored the int1 gene specific to the conserved integrase region of class 1 integrons. Sequence analysis revealed the dominance of dfrA and aadA gene cassettes among the isolates of both groups. ERIC-PCR fingerprinting of EPEC isolates revealed a high diversity among these isolates. The widespread distribution of 2 resistance gene families (dfrA and aadA) among both groups of EPEC and non-EPEC isolates indicates the significance of integrons in antibiotic resistance transfer among these bacteria. Furthermore, clonal diversity of EPEC isolates harbouring a class 1 integron also suggests the circulation of these mobile elements among a diverse population of EPEC in this country.     

Diversity of aminoglycoside modifying enzyme genes among multidrug resistant Acinetobacter baumannii genotypes isolated from nosocomial infections in Tehran hospitals and their association with class 1 integrons

The aim of the present study was to investigate, for the first time, the diversity of the genes encoding aminoglycoside-modifying enzymes (AME) and their association with class 1 integrons in Iranian Acinetobacter baumannii strains. A total of 100 multidrug resistant A. baumannii, isolated from eight distinct hospitals in Tehran, were enrolled in this study. Susceptibility of these isolates to antimicrobial agents including gentamicin and amikacin was determined by E-test. Aminoglycoside resistant isolates were then tested by PCR for AME genes, including aphA6, aacC1, aacC2, aacA4, aadB, aadA1, classes 1 integron, 5'-CS-3' and typed by RAPD PCR. The rate of resistance to imipenem, meropenem, gentamicin and amikacin were 39%, 39%, 38% and 32%, respectively. Intermediate resistance phenotype to gentamicin and amikacin was observed in 2% and 5% of all the isolates, respectively. After aph6 with 90% (n = 36/40), aadA1, aacC1 and aadB with 82.5% (n = 33/40), 65% (n = 26/40) and 20% (n = 8/40) were the most prevalent AME genes among aminoglycosides resistant A. baumannii isolates. A combination of two to four different resistance genes was observed in 39 of 40 strains (97.5%), with a total of 7 different combinations. PCR of integrase genes revealed that AME gene was associated with 67% of class 1 integrons. RAPD analysis showed three predominant genotypes A (n = 20), B (n = 10) and 10 unrelated genotypes. The occurrence of identical resistance genes, gene combinations and class 1 integrons associated with these genes in clonally distinct strains indicates that horizontal gene transfer plays a major role in the dissemination of aminoglycoside resistance in A. baumannii.     

Unnoticed spread of class 1 integrons in gram-positive clinical strains isolated in Guangzhou, China

A total of 46 gram-positive bacteria isolated from clinical specimens collected in China were subjected to PCR analysis with the intI1-specific primers, and the intI1-positive strains were further analyzed for their resistance gene cassette. All isolates possessed the class 1 integron in their genomes and the array of gene cassettes was dhfrXII-orfF-aadA2, which is very similar to other organisms except in one isolate carrying an additional copy of the class 1 integron containing the aadA2 gene cassette. Altogether, the results indicate that the class 1 integron is widespread in gram-positive clinical strains isolated in Guangzhou, China.     

整合子与多重耐药大肠埃希菌相关性研究

目的探讨整合子在多重耐药大肠埃希菌耐药性中的作用。方法对临床分离的93株多重耐药大肠埃希菌的I、Ⅱ型整合酶基因进行检测,并分析药敏结果。结果多重耐药临床分离株中Ⅰ型整合子阳性率为60.2%。所检出整合子共有3种长度即1000、1600和2000 bp;主要携带aadA和dfrA类基因盒;未检出Ⅱ型整合子。结论整合子形成是细菌产生多重耐药的重要原因。     

I类整合子与产ESBLs肺炎克雷伯菌多重耐药关系的研究

目的了解产ESBLs肺炎克雷伯菌的整合子存在状况。方法用PCR方法扩增Ⅰ类整合酶基因,经电泳后检测扩增产物。结果72株产ESBLs肺炎克雷伯菌中检测出Ⅰ类整合子67株,检出率为93．0％,Ⅰ类整合子阳性菌对氨基糖苷类、喹诺酮类及头孢菌素类药物表现出较高的耐药,其多重耐药率明显高于Ⅰ类整合子阴性菌株（P〈0．05）。结论Ⅰ类整合子广泛地存在产ESBLs肺炎克雷伯菌中,Ⅰ类整合子对细菌多重耐药性的产生和传播起着重要作用。     

产超广谱β-内酰胺酶大肠埃希菌Ⅰ类整合子检测与耐药性关系

目的了解I类整合子在产ESBLs和非产ESBLs大肠埃希菌中分布状况,分析I类整合子在细菌多重耐药中的作用。方法用PCR方法扩增I类整合酶基因,经电泳后检测扩增产物。用2χ检验进行统计学分析,P<0.05为差异有显著性。结果105株大肠埃希菌检出I类整合子46株,检出率为43.8%。I类整合子在产ESBLs菌的检出率为53.4%,明显高于非产ESBLs菌(31.9%),2χ检验,P<0.01。I类整合子阳性菌株多重耐药率为68.8%(33/48),明显高于阴性菌株(33.3%),P<0.05。I类整合子阳性菌株和产ESBLs菌均对青霉素类、喹诺酮类、磺胺类抗生素表现出较高的耐药率。所有菌株均对亚胺培南敏感。结论I类整合子携带与产ESBLs菌株耐药有关,I类整合子阳性菌株对多种抗生素的耐药率大于整合子阴性菌株。     

Vibrio cholerae non-O1, non-O139 strains isolated before 1992 from Varanasi, India are multiple drug resistant, contain intSXT, dfr18 and aadA5 genes

In this study, we report the presence of the SXT element and Class I integron in Vibrio cholerae non-O1, non-O139 strains isolated from Varanasi, India. Isolates were resistant to cotrimoxazole, trimethoprim and/or streptomycin, furazolidone and ampicillin. None contained plasmids. Polymerase chain reaction (PCR) and DNA sequencing revealed the presence of antibiotic resistance gene cassettes, aadA1 , aadA2 , aadA5 and dfrA15 , in the Class I integron and SXT, an integrative conjugative element containing dfr18 , sulII and strAB , in three and six of the isolates respectively. Conjugation experiments, followed by PCR analysis of transconjugants, provided evidence for the transferable nature of int SXT and associated antibiotic resistance gene cassettes. This is the first report of the occurrence of SXT ICE, dfr18 , sulII , strAB and aadA5 genes in environmental V. cholerae non-O1, non-O139 strains from Varanasi, India, that had been isolated before 1992.     

临床分离的变形杆菌中整合子分型研究

目的了解临床分离变形杆菌中1、2类整合子的流行现状及其耐药性。方法PCR扩增146株变形杆菌中1、2类整合酶基因,M-H肉汤稀释法检测146株变形杆菌的药敏情况。结果1类整合子检出率为36.9%(54/146),2类整合子检出率为38.4%(56/146),同时携带1、2类整合子的检出率为18.5%(27/146)。结论1、2类整合子在变形杆菌感染临床分离株中所占比例已相当高,1、2类整合子与变形杆菌的多重耐药具有相关性。     

肺炎克雷伯菌耐药性与I类整合子关系的研究

目的检测I类整合子在肺炎克雷伯菌临床分离株中的分布,分析整合子对细菌耐药性的影响。方法采用K—B纸片扩散法对127株肺炎克雷伯菌临床分离株进行药敏试验;并用WHONET5．6软件分析菌株药敏情况;采用聚合酶链反应（PCR）分析127株肺炎克雷伯菌株的I类整合子。并对I类整合子阳性株与阴性株的耐药性进行对比分析。结果127株菌中有53株（41．70％）含有I类整合子,I类整合子阳性菌株对氨基糖苷类、喹诺酮类及大多数B一内酰胺类的耐药率高于整合子阴性的菌株。结论I类整合子在肺炎克雷伯菌临床分离株存在较广,含有I类整合子的肺炎克雷伯菌更易获得耐药性。     

痰液中产ESBL肺炎克雷伯菌Ⅰ、Ⅱ类整合子检测及基因分型研究

目的研究临床痰液分离的产ESBLs肺炎克雷伯菌Ⅰ、Ⅱ类整合子分布情况,并进行基因分型。方法分离临床痰液中100株产ESBLs的肺炎克雷伯菌,用WHONET 5.4分析菌株药敏情况,PCR检测整合酶Ⅰ、整合酶Ⅱ,ERIC-PCR进行基因分型。结果 100株菌对碳青霉烯类敏感率100%,对β-内酰胺类、氨基糖苷类、氟喹诺酮类多数耐药。整合酶Ⅰ检出率为60%,未检出整合酶Ⅱ。100株菌分为72个基因型。结论Ⅰ类整合子广泛存在于产ESBLS肺炎克雷伯菌中,与肺炎克雷伯菌的耐药相关,ERIC-PCR可用于临床分离肺炎克雷伯的基因分型。